现实生活研究中生物可吸收血管支架失败的发生与处理
Occurrence and management of bioresorbable vascular scaffold failure in real-life studies.
作者信息
Cortese Bernardo, Elwany Mostafa
机构信息
Interventional Cardiology, ASST Fatebenefratelli Sacco, Milano, Italy.
Fondazione G. Monasterio CNR-Regione Toscana, Pisa, Massa, Italy.
出版信息
J Thorac Dis. 2017 Aug;9(Suppl 9):S935-S939. doi: 10.21037/jtd.2017.06.82.
Abstract
Bioresorbable vascular scaffold (BVS) has emerged as a new technology aiming at overcoming some drawbacks of the conventional metallic stent. In spite of the initial promising results, this technology stumbled upon numerous challenges, which were revealed in the real world studies. Thanks to real world trials and registries findings, our knowledge about the BVS has grown over time, thus we have understood on BVS behavior in various settings and formulated better implantation techniques. In this article, we will review the incidence of BVS failure in real world studies, its different etiologies and management strategies.
摘要
生物可吸收血管支架（BVS）已成为一项旨在克服传统金属支架某些缺点的新技术。尽管最初取得了令人鼓舞的结果，但这项技术在现实世界研究中遇到了众多挑战。得益于现实世界试验和注册研究的结果，我们对BVS的了解随着时间的推移不断增加，因此我们已经了解了BVS在各种情况下的表现，并制定了更好的植入技术。在本文中，我们将回顾现实世界研究中BVS失败的发生率、其不同病因及管理策略。
相似文献
1
Occurrence and management of bioresorbable vascular scaffold failure in real-life studies.
J Thorac Dis. 2017 Aug;9(Suppl 9):S935-S939. doi: 10.21037/jtd.2017.06.82.
2
Real-World Bioresorbable Vascular Scaffold Experience Compared With Second-Generation Metallic Drug-Eluting Stents in Complex Coronary Lesions.
J Invasive Cardiol. 2018 Jul;30(7):251-255. Epub 2018 Apr 15.
3
Patient profile and periprocedural outcomes of bioresorbable vascular scaffold implantation in comparison with drug-eluting and bare-metal stent implantation. Experience from ORPKI Polish National Registry 2014-2015.
Postepy Kardiol Interwencyjnej. 2016;12(4):321-328. doi: 10.5114/aic.2016.63632. Epub 2016 Nov 17.
4
Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials.
JACC Cardiovasc Interv. 2013 Mar;6(3):247-57. doi: 10.1016/j.jcin.2012.10.013.
5
Very Late Scaffold Thrombosis of Bioresorbable Vascular Scaffold: Systematic Review and a Meta-Analysis.
JACC Cardiovasc Interv. 2017 Jan 9;10(1):27-37. doi: 10.1016/j.jcin.2016.10.027.
6
The Current Literature on Bioabsorbable Stents: a Review.
Curr Atheroscler Rep. 2019 Nov 25;21(12):54. doi: 10.1007/s11883-019-0816-4.
7
Bioresorbable vascular scaffold versus metallic stent in percutaneous coronary intervention: results of the AIDA trial.
J Community Hosp Intern Med Perspect. 2017 Oct 18;7(5):307-308. doi: 10.1080/20009666.2017.1374111. eCollection 2017.
8
Vascular restoration therapy and bioresorbable vascular scaffold.
Regen Biomater. 2014 Nov;1(1):49-55. doi: 10.1093/rb/rbu005. Epub 2014 Oct 20.
9
Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population.
Catheter Cardiovasc Interv. 2015 Jan 1;85(1):E10-5. doi: 10.1002/ccd.25569. Epub 2014 Jul 16.
10
Twelve-Month Outcomes With a Bioresorbable Everolimus-Eluting Scaffold: Results of the ESHC-BVS Registry at Two Australian Centers.
J Invasive Cardiol. 2016 Aug;28(8):316-22. Epub 2015 Nov 15.
本文引用的文献
1
First experience of drug-coated balloons for treatment of bioresorbable vascular scaffold restenosis.
Cardiovasc Revasc Med. 2017 Oct-Nov;18(7):482-486. doi: 10.1016/j.carrev.2017.03.020. Epub 2017 Mar 25.
2
Restenosis of Coronary Bioresorbable Vascular Scaffolds.
Rev Esp Cardiol (Engl Ed). 2017 Jul;70(7):527-531. doi: 10.1016/j.rec.2017.02.024. Epub 2017 Mar 9.
3
Very Late Scaffold Thrombosis of Bioresorbable Vascular Scaffold: Systematic Review and a Meta-Analysis.
JACC Cardiovasc Interv. 2017 Jan 9;10(1):27-37. doi: 10.1016/j.jcin.2016.10.027.
4
Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial.
Lancet. 2016 Nov 19;388(10059):2479-2491. doi: 10.1016/S0140-6736(16)32050-5. Epub 2016 Oct 30.
5
Comparative Characterization of Biomechanical Behavior and Healing Profile of a Novel Ultra-High-Molecular-Weight Amorphous Poly-l-Lactic Acid Sirolimus-Eluting Bioresorbable Coronary Scaffold.
Circ Cardiovasc Interv. 2016 Oct;9(10). doi: 10.1161/CIRCINTERVENTIONS.116.004253.
6
First reported use of drug-coated balloon for bioresorbable in-scaffold restenosis.
Catheter Cardiovasc Interv. 2017 Mar 1;89(4):676-678. doi: 10.1002/ccd.26803. Epub 2016 Sep 21.
7
Overview of the 2016 U.S. Food and Drug Administration Circulatory System Devices Advisory Panel Meeting on the Absorb Bioresorbable Vascular Scaffold System.
JACC Cardiovasc Interv. 2016 Sep 12;9(17):1757-64. doi: 10.1016/j.jcin.2016.06.027.
8
The Contemporary Pulse of Bioresorbable-Scaffold Thrombosis Among Expert Operators.
J Am Coll Cardiol. 2016 Jun 21;67(24):2905-6. doi: 10.1016/j.jacc.2016.03.576.
9
Platelet reactivity over time in coronary artery disease patients treated with a bioabsorbable everolimus-eluting scaffold.
Platelets. 2016 Dec;27(8):777-783. doi: 10.1080/09537104.2016.1184750. Epub 2016 Jun 2.
10
Impact of the bioresorbable vascular scaffold surface area on on-treatment platelet reactivity.
Platelets. 2016 Jul;27(5):446-51. doi: 10.3109/09537104.2016.1143918. Epub 2016 Mar 4.
Zotero 插件